17-Allylamino-17-demethoxygeldanamycin (17-AAG) is effective in down-regulating mutated, constitutively activated KIT protein in human mast cells.

Mutations in the proto-oncogene c-kit cause constitutive kinase activity of its product, KIT protein, and are associated with human mastocytosis and gastrointestinal stromal tumors (GISTs). Although currently available tyrosine kinase inhibitors are effective in the treatment of GISTs, there has been limited success in the treatment of mastocytosis. 17-Allylamino-17-demethoxygeldanamycin (17-AAG), a benzoquinoid ansamycin antibiotic, which binds to heat shock protein 90 (hsp90) causes destabilization of various hsp90-dependent kinases important in oncogenesis. Treatment with 17-AAG of the mast cell line HMC-1.2, harboring the Asp816Val and Val560Gly KIT mutations, and the cell line HMC-1.1, harboring a single Val560Gly mutation, causes both the level and activity of KIT and downstream signaling molecules AKT and STAT3 to be down-regulated following drug exposure. These data were validated using Cos-7 cells transfected with wild-type and mutated KIT. 17-AAG promotes cell death of both HMC mast cell lines. In addition, neoplastic mast cells isolated from patients with mastocytosis, incubated with 17-AAG ex vivo, are selectively sensitive to the drug compared to the mononuclear fraction. These data provide compelling evidence that 17-AAG may be effective in the treatment of c-kit-related diseases including mastocytosis, GISTs, mast cell leukemia, subtypes of acute myelogenous leukemia, and testicular cancer.

[1]  S. Mandrekar,et al.  A phase I trial of 17-allylamino-geldanamycin (17AAG) in patients with advanced cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  L. Fritz,et al.  A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors , 2003, Nature.

[3]  B. Longley,et al.  Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit. , 2003, Experimental hematology.

[4]  R. Rottapel,et al.  Signal transduction by several KIT juxtamembrane domain mutations , 2003, Oncogene.

[5]  Avijit Chakrabartty,et al.  Autoinhibition of the Kit Receptor Tyrosine Kinase by the Cytosolic Juxtamembrane Region , 2003, Molecular and Cellular Biology.

[6]  Gabriela Chiosis,et al.  BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90. , 2002, Blood.

[7]  R. Jove,et al.  Molecular characterization and sensitivity of STI-571 (imatinib mesylate, Gleevec)-resistant, Bcr-Abl-positive, human acute leukemia cells to SRC kinase inhibitor PD180970 and 17-allylamino-17-demethoxygeldanamycin. , 2002, Cancer research.

[8]  H. Saito,et al.  Selective apoptosis of tandemly duplicated FLT3-transformed leukemia cells by Hsp90 inhibitors , 2002, Leukemia.

[9]  N. Rosen,et al.  Degradation of HER2 by ansamycins induces growth arrest and apoptosis in cells with HER2 overexpression via a HER3, phosphatidylinositol 3'-kinase-AKT-dependent pathway. , 2002, Cancer research.

[10]  L. Neckers,et al.  Hsp90 inhibitors as novel cancer chemotherapeutic agents. , 2002, Trends in molecular medicine.

[11]  M. Blagosklonny.  STI-571 must select for drug-resistant cells but ‘no cell breathes fire out of its nostrils like a dragon’ , 2002, Leukemia.

[12]  A. Ishida,et al.  Involvement of Hsp90 in Signaling and Stability of 3-Phosphoinositide-dependent Kinase-1* , 2002, The Journal of Biological Chemistry.

[13]  B. Druker,et al.  Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  J. Reilly.  Class III receptor tyrosine kinases: role in leukaemogenesis , 2002, British journal of haematology.

[15]  Shan Zeng,et al.  The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. , 2002, Blood.

[16]  N. Rosen,et al.  Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2 , 2002, Oncogene.

[17]  G. Nilsson,et al.  The Kit-activating mutation D816V enhances stem cell factor--dependent chemotaxis. , 2001, Blood.

[18]  R. Arceci,et al.  STAT3 activation is required for Asp816 mutant c-Kit induced tumorigenicity , 2001, Oncogene.

[19]  D. Metcalfe,et al.  Mastocytosis: molecular mechanisms and clinical disease heterogeneity. , 2001, Leukemia research.

[20]  Y. Ma,et al.  Classes of c-KIT activating mutations: proposed mechanisms of action and implications for disease classification and therapy. , 2001, Leukemia research.

[21]  P. N. Rao,et al.  Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification , 2001, Science.

[22]  R. Arceci,et al.  Signal transducer and activator of transcription 3 activation is required for Asp(816) mutant c-Kit-mediated cytokine-independent survival and proliferation in human leukemia cells. , 2001, Blood.

[23]  Y. Yarden,et al.  Sensitivity of Mature ErbB2 to Geldanamycin Is Conferred by Its Kinase Domain and Is Mediated by the Chaperone Protein Hsp90* , 2001, The Journal of Biological Chemistry.

[24]  T. Fojo,et al.  The Hsp90 inhibitor geldanamycin selectively sensitizes Bcr-Abl-expressing leukemia cells to cytotoxic chemotherapy , 2001, Leukemia.

[25]  L. Neckers,et al.  The heat shock protein 90 antagonist geldanamycin alters chaperone association with p210bcr-abl and v-src proteins before their degradation by the proteasome. , 2000, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[26]  D. Metcalfe,et al.  Kit signal transduction. , 2000, Hematology/oncology clinics of North America.

[27]  P. Peterlongo,et al.  C-kit mutations in core binding factor leukemias. , 2000, Blood.

[28]  S. R. Datta,et al.  Cellular survival: a play in three Akts. , 1999, Genes & development.

[29]  D. Linnekin,et al.  Early signaling pathways activated by c-Kit in hematopoietic cells. , 1999, The international journal of biochemistry & cell biology.

[30]  H. Alexander,et al.  Augmentation of melanoma-specific gene expression using a tandem melanocyte-specific enhancer results in increased cytotoxicity of the purine nucleoside phosphorylase gene in melanoma. , 1999, Human gene therapy.

[31]  D. Heitjan,et al.  Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[32]  Y. Ma,et al.  Clustering of activating mutations in c-KIT's juxtamembrane coding region in canine mast cell neoplasms. , 1999, The Journal of investigative dermatology.

[33]  J. Turkson,et al.  Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. , 1999, Immunity.

[34]  S. Hirota,et al.  Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. , 1998, Science.

[35]  L. Neckers,et al.  The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin , 1998, Cancer Chemotherapy and Pharmacology.

[36]  Y. Matsuzawa,et al.  Role of Aspartic Acid 814 in the Function and Expression of c-kit Receptor Tyrosine Kinase (*) , 1996, The Journal of Biological Chemistry.

[37]  Y. Suzuki,et al.  Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[38]  Mikhail V. Blagosklonny,et al.  Disruption of the Raf-1-Hsp90 Molecular Complex Results in Destabilization of Raf-1 and Loss of Raf-1-Ras Association (*) , 1995, The Journal of Biological Chemistry.

[39]  John Malysz,et al.  W/kit gene required for interstitial cells of Cajal and for intestinal pacemaker activity , 1995, Nature.

[40]  振津 琢磨.  Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product , 1995 .

[41]  L. Neckers,et al.  Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[42]  D. Bowen,et al.  Serum stem cell factor concentration in patients with myelodysplastic syndromes , 1993, British Journal of Haematology.

[43]  R. Fleischman.  From white spots to stem cells: the role of the Kit receptor in mammalian development. , 1993, Trends in genetics : TIG.

[44]  S. Lev,et al.  Structure‐function analyses of the kit receptor for the steel factor , 1993, Stem cells.

[45]  L. Neckers,et al.  Benzoquinonoid ansamycins possess selective tumoricidal activity unrelated to src kinase inhibition. , 1992, Cancer research.

[46]  H. Kitayama,et al.  Expression and functional role of the proto-oncogene c-kit in acute myeloblastic leukemia cells. , 1991, Blood.

[47]  C. March,et al.  Molecular cloning of mast cell growth factor, a hematopoietin that is active in both membrane bound and soluble forms , 1990, Cell.

[48]  David A. Williams,et al.  Stem cell factor is encoded at the SI locus of the mouse and is the ligand for the c-kit tyrosine kinase receptor , 1990, Cell.

[49]  P. Leder,et al.  The kit ligand: A cell surface molecule altered in steel mutant fibroblasts , 1990, Cell.

[50]  K. Zsebo,et al.  Primary structure and functional expression of rat and human stem cell factor DNAs , 1990, Cell.

[51]  F. Ruddle,et al.  Primary structure of c‐kit: relationship with the CSF‐1/PDGF receptor kinase family–oncogenic activation of v‐kit involves deletion of extracellular domain and C terminus. , 1988, The EMBO journal.

[52]  A. Ullrich,et al.  Human proto‐oncogene c‐kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. , 1987, The EMBO journal.

[53]  John E. Murphy,et al.  A new acute transforming feline retrovirus and relationship of its oncogene v-kit with the protein kinase gene family , 1986, Nature.

[54]  Josef Korinek,et al.  Proceedings of the American Society of Clinical Oncology , 1982 .